Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 14Pancreatic Neoplasms 5Colorectal Neoplasms 3Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2Advanced Non-Small Cell Lung Cancer 2Uterine Cervical Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pan-tumor 1Neoplasm Metastasis 1Locally Advanced Gastric or Gastroesophageal Junction Cancer 1Klatskin Tumor 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 2Cisplatin 23-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 2Tegafur 1Stents 1S 1 (combination) 1Hydroxychloroquine 1Drug Therapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Klatskin Tumor × S 1 (combination) × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡